Non-oral therapies burden PAH patients

Robyn Kalda
Aug 4, 2025
1 min read

This study looked at the challenges and impacts of non-oral treatments for pulmonary arterial hypertension (PAH), beyond those caused by PAH itself. They found that people taking oral-only therapies and people taking non-oral therapy had similar health, but those taking non-oral therapy had worse quality of life, as non-oral therapy interfered with daily activities.

Read the Therapeutic Advances in Respiratory Disease article

Recent Posts

Sotatercept and cardiopulmonary comorbidities

This study from one clinic examined how well sotatercept worked in real-world patients with pulmonary arterial hypertension (PAH) who also had other heart or lung conditions, such as coronary artery d

Start up: Supporting PAH patients beginning prostanoids

This study looked at a French support program designed to help people with pulmonary arterial hypertension (PAH) start and adjust their dose of selexipag. Nurses called patients three days after patie

Sotatercept vs. selexipag in severe PAH

Researchers used AI to indirectly compare data from three randomized controlled trials looking at sotatercept or selexipag in pulmonary arterial hypertension (PAH). Their findings suggest that sotater

Comments